Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

Annals of Oncology

Volumn 10, Issue 3, 1999, Pages 351-354

  Germann, N ^a   Brienza, S ^a   Rotarski, M ^a   Emile, J F ^b   Di Palma, M ^a   Musset, M ^a   Reynes, M ^b   Soulie P ^a   Cvitkovic, E ^a   Misset, J L ^a,b  

^a Federation des Maladies Sanguines   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Monotherapy; Non Hodgkin's lymphoma; Oxaliplatin; Salvage therapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; HISTAMINE H3 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; PROGNOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0032936294     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008310708853     Document Type: Article

References (12)

1. Harris NL, Jaffe ES, Stein H et al. A Revisited European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84 (5): 1361-92.
2. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. Hematol/Oncol Clin North Am 1997; 11 (5): 937-47.
3. Philip T, Gugliemi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared to salvage therapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
4. Raymond E, Chaney SG, Taamma A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71.
5. Weinstein JN, Myers TG, O'Connor PM. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343-9.
6. Machover D, Diaz-Rubio E, De Gramont A et al. Two consecutive phase II studies of oxaliplatin (1-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
7. Chollet P, Bensmaine MA, Brienza S et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-70.
8. Mathe G, Kidani Y, Sekiguchi M et al. Oxali-platinum or 1-OHP, a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43: 237-50.
9. Levi F, Missel JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992; 69 (4): 893-9.
10. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
11. Rossof AH, Coltman CA Jr, Jones SE, Talley RW. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: A Southwest Oncology Group study. Cancer Treat Rep 1979; 63: 1605-8.
12. Cavalli F, Jungi WF, Nissen NI et al. Phase II of cis- dichlorodiammineplatinum(II) in advanced malignant lymphomas: A study of the Cancer and Acute Leukemia Group. Cancer 1981; 48:1927-30.